Biogen reported poor efficacy of gosuranemab, an antibody that had been considered as a potential treatment for Alzheimer's disease. The phase II study found no treatment benefit on the efficacy endpoints studied, including the Alzheimer's Disease Rating Scale. The company is discontinuing clinical development of gosranemab and is seeking other approaches to treat the disease.